Prosecution Insights
Prosecution Insights
1 pending office actions • 0 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Mindrank Therapeutics (Suzhou) New Drug Research And Development Co. Ltd. currently has 1 pending office action. This matter is assigned to a distinct examiner and 0 distinct art units.
PATEL, SAGAR S is the busiest examiner, responsible for the 1 pending office action. Prosecution is currently focused on this examiner and the 0 distinct art units.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PATEL, SAGAR S | 1 | 75.7% | +34.9% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18996003 | POLYMORPHIC FORM OF GLP-1R AGONIST, PREPARATION METHOD THEREFOR AND USE THEREOF | PATEL, SAGAR S | — |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18996003 | POLYMORPHIC FORM OF GLP-1R AGONIST, PREPARATION METHOD THEREFOR AND USE THEREOF | PATEL, SAGAR S | — | §112Other | Non-Final OA | — | Pending | Jan 17, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMindrank Therapeutics (Suzhou) New Drug Research And Development Co. Ltd. has 1 pending office actions as of October 2026, spread across 0 art units and 1 examiners.
Sagar S Patel has the most, with 1 of Mindrank Therapeutics (Suzhou) New Drug Research And Development Co. Ltd.'s pending office actions.